A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: HX008+Cisplatin+Gemcitabine
Sponsor: Taizhou Hanzhong biomedical co. LTD